People with cancer receiving immunotherapy or other anticancer treatments are at increased risk for adverse COVID-19 outcomes if they are also receiving immunosuppressive therapy, suggests a registry-based cohort study.
A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.
Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.